Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design

Repros Therapeutics Inc.^® RPRX today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application. Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!